Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cevimeline - Daiichi Sankyo

Next Previous
X
Search
Drug Profile

Cevimeline - Daiichi Sankyo

Alternative Names: AF 102B; Cevimeline hydrochloride; Evoxac; FKS 508; Saligren; SND 5088; SNI 2011; SNK 508

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Israel Institute for Biological Research
  • Developer Daiichi Sankyo Company; Nippon Kayaku; SnowBrand Pharmaceuticals
  • Class Quinuclidines; Small molecules; Thiophenes
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Xerostomia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Jan 2022 Cevimeline licensed to Cosette Pharmaceuticals in USA
  • 26 Feb 2021 Daiichi Sankyo Company plans to transfer rights of Evoxac to Alfresa Pharma by December 2021
  • 09 Oct 2012 Authorised generic equivalent available in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top